{"entity":{"id":"nct06011109","kind":"trial","name":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab","aka":[],"tldr":"A phase 1/2 trial of APG-157 in glioma & glioblastoma, run by Aveta Biomics, Inc., now recruiting.","summary":"Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab is a phase 1/2 interventional study registered as NCT06011109 by Aveta Biomics, Inc., with 30 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: APG-157.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06011109","url":"https://clinicaltrials.gov/study/NCT06011109"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["aveta-biomics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06011109","phase":"1/2","setting":"A Pilot Study of APG-157 With Bevacizumab for Patients With Recurrent High-Grade Glioma","sponsor":"Aveta Biomics, Inc.","enrolled":30,"outcomes":[]},"route":"/trials/nct06011109/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"aveta-biomics","kind":"company","name":"Aveta Biomics","route":"/companies/aveta-biomics/"}]}}